Updated results of the Phase II MOMENTUM trial of Altimmune Inc.’s obesity candidate pemvidutide have allowed the company to regain some of the ground it lost in March when an earlier cut from the same study revealed worryingly high discontinuations.
Key Takeaways
- Updated data on Altimmune’s GLP-1/glucagon co-agonist pemvidutide are better than an earlier cut
The new data reveal improved efficacy and lower discontinuations, and Altimmune’s shares opened up by 83% at $5.80 on the...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?